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Abstract We have previously described the development
and implementation of a strategy for production of
recombinant polyclonal antibodies (rpAb) in single batches
employing CHO cells generated by site-speciﬁc integra-
tion, the Sympress
TM I technology. The Sympress
TM I
technology is implemented at industrial scale, supporting a
phase II clinical development program. Production of
recombinant proteins by site-speciﬁc integration, which is
based on incorporation of a single copy of the gene of
interest, makes the Sympress
TM I technology best suited to
support niche indications. To improve titers while main-
taining a cost-efﬁcient, highly reproducible single-batch
manufacturing mode, we have evaluated a number of dif-
ferent approaches. The most successful results were
obtained using random integration in a new producer cell
termed ECHO, a CHO DG44 cell derivative engineered for
improved productivity at Symphogen. This new expression
process is termed the Sympress
TM II technology. Here we
describe proof-of-principle data demonstrating the feasi-
bility of the Sympress
TM II technology for single-batch
rpAb manufacturing using two model systems each com-
posed of six target-speciﬁc antibodies. The compositional
stability and the batch-to-batch reproducibility of rpAb
produced by the ECHO cells were at least as good as
observed previously using site-speciﬁc integration tech-
nology. Furthermore, the new process had a signiﬁcant titer
increase.
Keywords Antibody production 
Recombinant polyclonal antibodies  Clonal cell lines 
Compositions of cell lines  DHFR selection 
Random integration  CHO-DG44 
Batch-to-batch consistency  Single-batch manufacturing
Introduction
Plasma-derived immunoglobulins have been used for pas-
sive immunotherapy for more than a century [1]. Current
use of this type of products includes: treatment of infec-
tions with hepatitis B virus, cytomegalovirus, and rabies
virus, while plasma-derived immunoglobulin containing
anti-Rhesus D antibody is in use for prevention of hemo-
lytic disease of the newborn and treatment of idiopathic
thrombocytopenic purpura [2–4]. Plasma-derived immu-
noglobulins are, however, associated with several disad-
vantages such as low efﬁcacy due to a low concentration of
antigen-speciﬁc antibodies and potential safety issues due
to the risk of disease transmission. Target-speciﬁc recom-
binant polyclonal antibodies (rpAb) would potentially
overcome these problems [5–7].
Monoclonal antibodies, the second generation of anti-
body therapeutics, have been in medical use since the late
1980s. Monoclonal antibodies overcome the above-men-
tioned shortfalls of plasma-derived immunoglobulins, but
they are less effective against diseases where a complex
antigen is the cause [8]. Because monoclonal antibodies
bind to only one single structure out of many on the surface
of a complex antigen, they are less likely to be able to
completely neutralize or eliminate that antigen.
Methods for development and manufacture of recom-
binant monoclonal antibodies are well established [9–11].
However, a new strategy is required to allow adaptation of
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substantially increasing the costs of production and regu-
latory approval.
Target-speciﬁc rpAb is a new generation of antibodies
mimicking the diversity, speciﬁcity, and binding capability
of the natural human immune system. To do this an rpAb
preparation will often contain several speciﬁc antibodies,
and for economic reasons a manufacturing procedure with
all antibodies being produced in the same culture vessel
will be preferable. Obviously, the ability to maintain the
same antibody composition between batches, the so-called
batch-to-batch consistency, is crucial for getting rpAb
approved for human therapeutic use. Maintaining batch-to-
batch consistency is complicated by the fact that the
method entails culturing of different cell lines with
potentially different speciﬁc productivities and growth
rates.
We have previously published a controlled method for
production of rpAb using site-speciﬁc integration technol-
ogy [12] to minimize differences in growth rate and
productivity from genomic position effects [13]. This
technology (named Sympress
TM I) is being used for the
production of an rpAb against the RhD antigen consisting
of 25 individual antibodies. This manufacturing strategy
has proven to result in highly consistent rpAb compositions
from batch-to-batch. The product Sym001 (Rozrolimupab)
is presently in clinical phase II. While Sympress
TM I is well
suited for manufacturing of anti-Rhesus D rpAb, where the
drug product demands on a yearly basis are relatively
small, certain indications with a high product demand (e.g.,
many cancers) require a higher production level. For this
purpose we have tested a number of alternative approaches.
The most successful results regarding productivity and
batch-to-batch consistency were obtained using a random
integration approach. The feasibility of this approach was
demonstrated in a new producer cell termed ECHO, a CHO
DG44 cell derivative engineered for improved productivity
at Symphogen. Using this system we were able to improve
productivity signiﬁcantly in a fed batch manufacturing
process and at the same time keep the polyclonal compo-
sition consistent from batch-to-batch.
Materials and Methods
Generation of the ECHO Cell Line
The mammalian expression cell line used is a derivative of
the DHFR-negative Chinese Hamster Ovary (CHO) cell
line DG44 kindly provided by Dr. Lawrence Chasin,
Columbia University (also available from Gibco cat #
12613-014). The DG44 cells were transfected with a cDNA
encoding the 13S version of the adenovirus type 5
transactivator E1A (NCBI accession no. AY339865) in
the vector pcDNA3.1 ? (Invitrogen). Transfectants were
selected with Geneticin (Invitrogen) and single-cell cloned
by limiting dilution. A clone showing a transient antibody
expression level increased by a factor of 3 compared to the
untransfected DG44 cell line was termed the ECHO cell
line.
Antibody Expression Vector
The employed antibody expression vector is shown in
Fig. 1a. Antibody heavy and light chain expression is
driven by two identical bi-directional human CMV
Fig. 1 a Mammalian expression vector used for expression of the
anti-Vaccinia and anti-RSV antibodies. CMV human CMV promoters,
VH antibody heavy chain variable region, IgG1 constant genomic
DNA encoding the human IgG1 constant region, IRES ? DHFR
ECMV internal ribosome entry sequence ? mouse DHFR cDNA,
SV40 poly A the SV40 polyadenylation sequence, bla and Amp
ampicillin resistance gene, pUC ori pUC origin of replication, bGH
poly A bovine growth hormone polyadenylation sequence, LC
antibody light chain cDNA. b Comparison of speciﬁc productivities
in selected pools of DG44 and ECHO cells. DG44 cells and ECHO
cells were transfected with three different anti-Vaccinia virus
antibody constructs (Ab numbers refer to the numbers used in
Fig. 2). Speciﬁc productivities were measured in selected pools
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used as selection marker. DHFR expression is coupled to
expression of the antibody heavy chain by an encepha-
lomyocarditis virus (EMCV) internal ribosome entry site
(IRES).
Antibodies
For initial proof-of-principle experiments six different
IgG1 kappa antibodies directed against different Vaccinia
virus surface proteins were isolated using the Symplex
TM
technology [14]. The genes encoding the variable heavy
and light chains of the individual antibodies were each
cloned into the mammalian cell expression vector shown in
Fig. 1a. The antibodies are further described in WO 2007/
065433.
For the second model system, six different respiratory
syncytial virus (RSV) speciﬁc IgG1 kappa antibodies iso-
lated from infected individuals using the Symplex
TM
technology and selected for reactivity with the RSV F- and
G- surface proteins were used.
Stable Transfection of ECHO Cells and Single Cell
Cloning by FACS
ECHO cells were seeded in T80 ﬂasks at a density of
0.15 9 10
6 cells/ﬂask in MEM alpha medium with
nucleosides (MEMalpha ? medium; Invitrogen) with 10%
fetal calf serum (FCS) (Invitrogen). After 24 h the cells
were transfected using Fugene6 (Roche) according to the
manufacturer’s instructions.
Pools of transfectants were selected with 2 nM (for
generation of anti-Vaccinia antibody-expressing ECHO
cells) or 3 nM (for generation of anti-RSV antibody-
expressing ECHO cells) methotrexate (MTX) in nucleo-
side-free medium supplied with 10% dialyzed FCS
(MEMalpha-medium). The MTX-selected pools were sin-
gle-cell cloned by FACS based on high cell surface
expression of IgG. Brieﬂy, cells were detached, stained
with phycoerythrin-coated goat anti-human IgG (IM1626,
Beckman Coulter) and single-cell sorted by gating the
upper (with regard to Mean Fluorescence Intensity) 1–2%
into 96-well plates containing 100 ll of a 1:1 mix of
MEMalpha-medium to conditioned MEMalpha ? medium
from non-transfected ECHO cells. No MTX was added to
the culture medium from this point. The 96-well plates
were visually screened for the presence of single-cell
clones and after 10–13 days supernatants were screened by
IgG ELISA. ELISA values and visual inspection of the
degree of conﬂuence in the wells were used to select clones
for further culture.
Selected clones were transferred and propagated in T80
ﬂasks and speciﬁc productivities were measured by IgG
ELISA. The results were used to select clones for cryo-
preservation and adaptation to serum-free suspension
culture.
Adaptation to Serum-free Suspension Culture
in ProCHO4
Adherent cells were adapted to serum-free suspension
culture in ProCHO4 medium (ProCHO4 (Lonza), 4 mM
L-glutamine (Invitrogen), 1% non-essential amino acids
(Invitrogen), anti-clumping agent 1:250 (Invitrogen)) in
aerated 50 ml cell culture tubes (TPP). The tubes were
placed in a shaker incubator at 37 C and 5% CO2 at a
shaking speed of 200 rpm. The medium was changed or
the cultures diluted as needed. When growth was vig-
orous (doubling time below 30–35 h) the cells were
considered adapted, after which they were expanded and
frozen.
Adaptation to Chemically Deﬁned Medium
The anti-RSV ECHO clones in ProCHO4 medium were
transferred to shaker ﬂasks in chemically deﬁned medium
at a shaking speed of 100 rpm. Medium exchange or
dilution of cultures was performed when needed. The
adaptation lasted around 3 weeks and was considered
complete when doubling times were stable and below
35 h.
Co-Cultivation of Six Anti-Vaccinia Clones
The anti-Vaccinia co-cultivation experiment was per-
formed in aerated 50 ml culture tubes in a total volume of
10 ml. The experiment was started with a cell concentra-
tion of 0.3 9 10
6 cells/ml. The cultures were diluted to
0.3 9 10
6 cells/ml twice a week with 3 and 4 days inter-
vals. Once a week samples for ELISA and cation exchange
chromatography (CIEX) analysis were taken starting on
day 4 and ending on day 35.
Preparation of Polyclonal Cell Banks
The two-tiered preparation of polyclonal cells banks is
shown schematically in Fig. 4. Brieﬂy, the chosen clones in
logarithmic growth phase were mixed, aliquoted, and fro-
zen in a number of ampoules (polyclonal master cell bank
(pMCB)). Polyclonal working cell banks (pWCB) were
prepared by thawing a pMCB ampoule, expanding the
cells for a period, aliquoting and freezing a number of
pWCB ampoules. The exact culture period at each step and
the number of cells frozen differed from experiment to
experiment (see ‘‘Results’’ section).
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For the fed batch productions of the anti-Vaccinia rpAb
compositions, one pWCB ampoule was thawed and trans-
ferred to ProCHO4 medium in a shaker ﬂask and incubated
at 37 C and 5% CO2. The cells were counted three times a
week and diluted while expanding the volume as necessary.
After 14 days, a 500 ml DASGIP bioreactor was inocu-
lated with 0.6 9 10
6 cells per ml in 250 ml ProCHO4
medium at 80 rpm and 37 C. The culture was fed with
ProCHO4 in a growth-rate-dependent manner up to 120 h,
after which the feed was decreased gradually. Concentra-
tions of glucose and L-glutamine were adjusted throughout,
and sodium bicarbonate was used for pH adjustment. IgG
product titer was determined by IgG speciﬁc HPLC. The
cultivation was continued until the cell viability was below
70% (around 16 days) and the cells were removed from the
supernatant by centrifugation and sterile ﬁltration.
The fed batch productions of the anti-RSV rpAb com-
positions were performed in a similar manner, except that
a chemically deﬁned medium was used instead of the
ProCHO4 medium and that a chemically deﬁned feed was
used instead of ProCHO4.
IgG ELISA
IgG was measured by sandwich ELISA. Brieﬂy, 96-well
plates (Maxisorp, NUNC) were coated with goat anti-
human Fc (Serotec, STAR106) followed by incubation
with samples and standard (a puriﬁed human monoclonal
IgG1 kappa antibody). Detection was performed with goat
anti-human kappa light chains conjugated with horseradish
peroxidase (Serotec STAR100P).
Measurement of IgG Concentration by HPLC
Cell supernatants were centrifuged at 14,0009g, diluted
1:1 with PBS and sterile ﬁltrated through a Millex-GV
SLGV013SL Durapore 0.22 lm ﬁlter. Samples were run
on a Poros A column (2.1 9 30 mm
2, Applied Biosys-
tems). 5–1000 ll were injected depending on the IgG
concentration. Solvents: A Solvent: 19 PBS, B Solvent:
12 mM HCl; 150 mM NaCl, C Solvent: 20% Acetic Acid;
0.3 M MgCl2. System: Dionex HPLC Summit system with
Pump p680—UVD170U detector—ASI-100 automated
sample injector with 1000 ll loop. A puriﬁed monoclonal
IgG1 kappa antibody was used as standard.
Puriﬁcation
The anti-Vaccinia virus recombinant polyclonal antibodies
were puriﬁed on a 1 ml MabSelect SuRe column (GE
Healthcare) pre-equilibrated in PBS, pH 7.4. After loading
with 5–10 ml 0.22 lm ﬁltered medium supernatant, the
column was washed with 10 ml PBS pH 7.4 and eluted
with 0.1 M glycine, pH 2.7. The eluted product was dia-
lyzed twice against 50 mM Na-acetate, 40 mM NaCl, pH
5.0. For the anti-RSV rpAb the same puriﬁcation procedure
was applied with a load of approximately 15 ml on a 50 ll
self-packed column (Poly-Prep Column, Bio-Rad). The
eluted product (250 ll) was adjusted to pH 7.0 using 4.5 ll
1.0 M Tris base.
Total IgG concentration was determined by measuring
the absorbance at 280 nm.
CIEX Chromatography
The puriﬁed anti-Vaccinia virus rpAb samples were ana-
lyzed by CIEX on a PolyCat A column (4.6 9 100 mm
2,
3 lm, 1500 A ˚ from PolyLC Inc., Columbia, MD). The
puriﬁed anti-RSV rpAb samples were analyzed by CIEX
on a ProPac WCX-10 column (4 9 250 mm
2 from Dio-
nex). Both columns were equilibrated in 25 mM sodium
acetate, pH 5.0, before application of 60 lg of the IgG
mixture with a ﬂow rate of 1 ml/min.
The anti-Vaccinia virus antibody peaks were subse-
quently eluted with a linear gradient from 150 to 500 mM
NaCl in 25 mM sodium acetate, pH 5.0 over 44 CV. The
anti-RSV antibody peaks were eluted with a linear gradient
from 125 to 350 mM NaCl in 25 mM sodium acetate, pH
5.0, in 10 column volumes. The antibody peaks were
detected spectrophotometrically at 215 nm. The chro-
matograms were peak integrated and the relative areas of
the individual peaks determined.
Results
Derivation of the ECHO Cell Line
CHO DG44 cells were transfected with a cDNA for the
adenoviral transactivator E1a and transfectants were
selected with G418. Clones were screened in a transient
transfection assay with an antibody expression construct.
One clone showed consistently more than a factor 3
improvement in ﬁnal antibody titer. This clone was sub-
cloned twice and termed the ECHO cell line. Transient
transfections with CMV-based EGFP constructs similarly
showed increased expression in the ECHO cell line.
Experiments aiming at identifying E1a transcripts by
quantitative PCR in the cell line have been unsuccessful
(not shown) so it is not clear whether E1a expression is
mediating the higher expression or whether the cell has
gained improved expression characteristics by random
means during sub-cloning.
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an increased expression in stable cell lines we did a pool
transfection experiment comparing the DG44 and ECHO
cell lines. The cells were each transfected with three con-
structs encoding different antibodies against Vaccinia virus
and transfectants were selected in nucleoside-free medium.
Figure 1b shows speciﬁc productivities at the pool level
indicating that the ECHO cell line gives productivities that
are 3–5 times as high as for the DG44 cell line.
A number of antibody-expressing ECHO clones derived
by the procedures described here were used for determi-
nation of copy number of the integrated construct by
Southern blotting and quantitative PCR, and we typically
found copy numbers above 100 (not shown).
Initial Co-Cultivation of ECHO Clone rpAb
Compositions
With the aim to investigate whether different stable anti-
body-expressing ECHO cell clones generated by means of
random integration could be cultivated together to produce
an rpAb in a reproducible manner without skewing the com-
position or losing diversity, a model study was designed as
follows: six different anti-Vaccinia antibodies were selec-
ted, each of them having a characteristic cation exchange
chromatography (CIEX) proﬁle distinguishable from the
others. This facilitated identiﬁcation and quantiﬁcation of
the six different antibodies in the compositions. ECHO cells
were transfected individually with six different plasmids
encoding anti-Vaccinia antibodies and selected for stable
expression using the DHFR gene as selection marker. High-
producing ECHO clones were isolated by surface labelling
of the selected cell pool with ﬂuorescent anti-IgG antibody
followedbysingle-cellsortingbyFACSofthe1–2%highest
expressing cells into wells containing ECHO cell condi-
tioned medium. Twenty four clones were selected for each
antibodybasedonELISAscreeningofproductionlevelsand
visual inspection for growth. These 6 9 24 clones were
tested in a 24-well medium exhaustion assay and the 10
highest producing clones for each antibody were adapted to
serum-free ProCHO4 medium. Some clones were discarded
during adaptation due to poor growth or decreasing pro-
ductivity. When adaptation was ﬁnished 5–7 cell clones
remained for each antibody. These were all frozen.
To test compositional stability of mixed cultures over a
long time a number of ECHO clone compositions were
prepared that would produce an rpAb consisting of the six
different anti-Vaccinia antibodies. Based on cell counting
during the late phase of the adaptation period clone
doubling times were calculated and taken into consider-
ation in the design of compositions to match clones with
similar doubling time. Altogether nine compositions were
prepared:
• Compositions 1–5: Each antibody was represented by a
single clone
• Composition 6: Two clones were used for each
antibody
• Composition 7: Five clones were used for each
antibody
• Composition 8: Three clones were used for each
antibody
• Composition 9: All available clones were used, 5–7 for
each antibody.
Clones were mixed so that the number of cells
expressing each antibody (for each antibody 1–7 different
ECHO clones) constituted 1/6 of the total number of cells
in the mixed composition.
The idea behind the use of more than one clone for each
antibody was that if a clone was lost due to poor growth
there were replacement clones present which overall would
increase the chance of having all antibodies represented in
the ﬁnal mix.
The cultivation experiment was performed for a period
of 5 weeks. Once a week samples for ELISA and CIEX
were taken. The cellular productivity as measured by
ELISA was relatively constant over the 5 week period with
a tendency toward a slight decline in some compositions
(results not shown).
The relative content of the six individual antibodies was
measured by CIEX at the start and end of cultivation of the
nine rpAb cultures (Fig. 2). All antibodies could be
detected in all nine cultures both at the start and the end of
the experiment. In all cultures, changes in the amount of
some of the individual antibodies were seen; in the ﬁnal
compositions individual antibodies constituted between 1.7
and 65%. There was not a clear tendency toward less
skewing in composition in cultures with more than one
ECHO clone representing each antibody (compositions 6–9
in Fig. 2).
The number of generations was between 25 and 27. This
means that if the cultures had been expanded in full volume
every time, the ﬁnal total volumes would be 43,000–
172,000 l. Large scale mammalian cell culture manufac-
turing processes in the industry are typically up to 15,000 l.
It should however be emphasized that this initial experi-
ment did not include cell banks, which means that fewer
generations were needed from the ﬁrst mixing of cells to
the end point measurement compared to an industrial
manufacturing process. Nevertheless, it was encouraging to
ﬁnd that the drift seen over this long period of co-culture
was not more pronounced.
Based on these initial experiments a new set of experi-
ments was designed: four new compositions were gener-
ated from clones producing the six antibodies replacing cell
lines with unwanted behavior (pronounced drift up or
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The compositions were 1A, 2A, 3A, and 4A of which
1A–3A contained one ECHO clone per antibody and 4A
contained three ECHO clones per antibody. To better
mimic a real manufacturing situation, polyclonal master
and working cell banks (pMCBs and pWCBs) were pre-
pared and a production phase was performed in bioreactors.
The results showed that by removing clones with unwanted
characteristics, the new compositions showed a less pro-
nounced skewing of the antibody composition during the
culture period. Furthermore, when the compositions were
produced in duplicate using separate parallel production
runs and starting seed-train expansions by thawing of dif-
ferent pWCB ampoules a high degree of batch-to-batch
consistency resulted for all four compositions (Fig. 3).
Overall, these ﬁrst experiments were promising regard-
ing the possibilities for producing rpAb in a reproducible
manner using an iterative process for the selection of an
appropriate composition of clones. The following experi-
ments were initiated to conﬁrm its usefulness using a dif-
ferent viral target.
Preparation of Anti-Respiratory Syncytial Virus rpAb
Compositions
Next, the feasibility of the Sympress
TM II system was
tested using a completely different rpAb composition,
consisting of six antibodies all targeting the Respiratory
Syncytial virus (RSV). For each of the six antibodies at
least six different stable ECHO clones were generated and
banked individually. Compositional stability studies with
different combinations of the anti-RSV antibody-express-
ing ECHO clones were performed in suspension culture in
chemically deﬁned medium.
In order to mimic a large scale industrial manufacturing
process studies were performed according to the scheme in
Fig. 4. Different rpAb combinations of the anti-RSV
ECHO clones were mixed and banked as pMCBs, followed
by preparation of pWCBs. pWCB ampoules were thawed,
seed-train expansion was performed in shaker ﬂasks, and a
production run was performed in 500 ml DASGIP biore-
actors using a fed batch process as typically used also for
mAb manufacturing. The studies were designed to simulate
all the steps included in an industrial manufacturing pro-
cess at 5,000–10,000 l scale as closely as possible. Thus,
before banking of the pWCB as well as during seed-train
expansion before inoculation of the bioreactor the cells
were cultivated for the number of generations required to
perform these steps in a scaled-up industrial process. The
relative amounts of the individual antibodies in the rpAb
compositions were analyzed by CIEX at the end of the
experiment. An example of a CIEX proﬁle of an anti-RSV
composition is shown in Fig. 5. The single anti-RSV
antibodies elute in distinct peaks and can be individually
quantiﬁed by integration of the peak areas.
In an exploratory ﬁrst set of compositional stability
studies different compositions were prepared by combining
clones with as similar doubling times as possible. Apart
Fig. 2 Relative content of six
anti-Vaccinia antibodies in nine
compositions maintained in
co-culture in 50 ml culture
tubes for 6 weeks. The nine
compositions containing six
different anti-Vaccinia
antibodies (I–VI) with one or
more clonal ECHO cell line(s)
expressing each antibody were
prepared as described in
‘‘Materials and Methods’’
section. Supernatants were
analyzed for content of the
individual antibodies by CIEX
at the start (dark gray columns)
and end (light gray columns) of
the cultures. The relative
content of the six antibodies
(along the horizontal axis)i s
given as percentage of total
antibody (vertical axis)
262 Mol Biotechnol (2010) 45:257–266from testing compositions with one ECHO clone per
antibody, we also tested a composition in which each
antibody was represented by three different clones. The
compositions were frozen as pMCBs, thawed again and
expanded for an appropriate number of generations ([8)
before preparation of pWCBs. Two pWCB ampoules were
thawed for each composition to start parallel seed-trains.
This was done in order to examine reproducibility of the
production runs. Seed-train expansion was performed in
shaker ﬂasks. The relative antibody composition in the
duplicate production runs was monitored by CIEX and the
reproducibility of the duplicate runs was found to be
acceptable.
However, in all compositions a tendency toward some
antibodies dominating the cultures and other antibodies
decreasing in quantity was observed (data not shown).
The composition consisting of three ECHO clones per
antibody resulted in a highly skewed composition after
fed batch production. Based on these results, and because
rpAb compositions prepared with one clone representing
each antibody provides a simpler approach with respect
to cell line characterization, it was decided to concentrate
on one-clone-per-antibody compositions. The observa-
tions from the exploratory compositional study were used
for preparation of new modiﬁed clone compositions (see
below).
Fig. 3 Relative content of six
anti-Vaccinia antibodies from
two independent fed batch runs
of each of the rpAb
compositions 1A, 2A, 3A, and
4A, performed in DASGIP
bioreactors at 500 ml scale as
described in ‘‘Materials and
Methods’’ section. The
compositions 1A–3A contained
one ECHO clone per antibody
and 4A contained three ECHO
clones per antibody. Samples
for CIEX proﬁle analysis were
taken on day 16 of the
bioreactor run
Fig. 4 Experimental setup of the compositional stability studies with
compositions expressing the anti-RSV rpAb. Suspension ECHO cell
clones expressing each of the six monoclonal anti-RSV antibodies
were banked individually. Selected ECHO clones, one for each of the
six anti-RSV antibodies, were thawed and mixed. The mixed
compositions were immediately frozen as polyclonal master cell
banks (pMCB). One ampoule of the pMCB was subsequently thawed,
expanded, and frozen as polyclonal working cell bank (pWCB).
pWCB cells were then thawed and seed-train expanded prior to a fed
batch production run in bioreactors
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clones which had contributed to compositional instability
by either taking over or disappearing from the culture
with other clones showing better characteristics. Seed-
trains and production runs were performed in duplicate for
each composition after thawing of two different pWCB
ampoules and following a seed-train and fed batch pro-
duction scheme mimicking an industrial process at 5,000–
10,000 l, as described above and in Fig. 4. In this set of
experiments, several compositions were generated with an
acceptable distribution of the individual antibodies after the
production run. Also, the reproducibility of the parallel
seed-trains and production runs was high (Fig. 6a, b).
In a third round of compositional stability studies the
information gained on the different ECHO clones in the
two previous studies was used by combining clones with
matching growth properties and productivities. The
experiment was designed essentially as before. In this
study compositions were generated with a more equal
distribution of the antibodies after the production run
(Fig. 6c). Here, the relative concentration of the single
antibodies was between 12 and 25% at the end of the
production run.
In order to conﬁrm the batch-to-batch consistency we
repeated seed-train expansion and fed batch production of
composition I (Fig. 6a). The polyclonal seed-trains were
run in four parallel shaker ﬂasks and DASGIP bioreactors.
The cells used for the four runs originated from four sep-
arately thawed ampoules of the pWCBs. Fed batch runs
were as described before and CIEX proﬁles of supernatants
were analyzed at day 10 of the fed batch process. As Fig. 7
indicates, the batch-to-batch variation within the four par-
allel runs was low. Also, the relative individual antibody
concentrations in the supernatant harvested from these
consistency runs were similar to the antibody concentra-
tions obtained in the previous study. Slight differences
might be explained by the different timing of sample taking
(10 days vs. 12 days).
Fig. 5 CIEX proﬁle of an anti-RSV rpAb composition containing six
different anti-RSV speciﬁc antibodies (Ab1–Ab6). The borders of the
six individual peaks are marked by the vertical lines. Integration of
the area of the individual peaks is used for relative quantiﬁcation of
the antibodies in the rpAb
Fig. 6 Relative concentrations of the six different anti-RSV antibod-
ies after single-batch manufacturing in fed batch mode. Three
different combinations of stable ECHO clones expressing the anti-
RSV rpAb were prepared and tested for compositional stability in a
fed batch setup at 500 ml scale designed to simulate production at
5,000–10,000 l scale. The supernatant harvested after single-batch
manufacturing was puriﬁed by protein A capture and the antibody
compositions were analyzed by CIEX. The CIEX peaks were
quantiﬁed by integration to obtain the relative distribution of the
individual antibodies in the compositions. a Composition I, b
composition II, c composition III. All runs were performed in
duplicate
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Here we describe the production of target-speciﬁc rpAb
compositions exempliﬁed by two completely different anti-
body compositions, namely an anti-Vaccinia virus rpAb and
an anti-RSV rpAb, each comprised of six different IgG1
kappa antibodies speciﬁc for their intended target, using
stable transfection of cells by random integration and pro-
ductioninasingle-batchformat.Surprisingly,theconceptof
using random integration turned out to be successful in both
cases, which makes us suggest that the concept may be
generally applicable for rpAb manufacturing. In bioreactor
experiments simulating a 5,000–10,000 l production using
extended seed-trains, the relative antibody compositions
were very similar in parallel production runs. This indicates
that batch-to-batch reproducibility, which is mandatory for
regulatory approval of rpAbs as human therapeutics, is
achieved by this manufacturing strategy. Furthermore,
extrapolating the laboratory scale result to industrial manu-
facturing scale, the Sympress
TM II platform provides sufﬁ-
cient yields to support commercially sound cost-of-goods.
Along with the Sympress
TM expression platform develop-
ment a release and characterization strategy for regulatory
approval of rpAb for clinical use have been established and
several methods addressing the compositional variability of
rpAb products have been established [3, Persson, P.,
Development of mass spectrometry based methods for
identiﬁcationanddeterminationofcompositionalvariability
in recombinant polyclonal antibody products, unpublished
results].
Having established a consistent rpAb batch-to-batch
reproducibility, we wanted to explore to which extent the
relative content of the antibodies in a composition could be
controlled. For most indications one would envision that a
1:1:1:… antibody distribution would be beneﬁcial, while
other antibody ratios could be optimal for certain indica-
tions. Thus, with the goal to achieve a relatively equal
distribution of the six antibodies in the ﬁnal RSV rpAb
composition an iterative approach where clones were
mixed based on growth characteristics and productivity
was shown to work. The data from the ﬁrst compositions
were used to exclude clones that behaved in an undesired
manner, showing differential growth compared to the other
clones or, alternatively, changing productivity over time. In
new experiments it was possible to achieve compositions
with a relatively equal distribution of the six antibodies
after completion of the production phase.
It is well-known that CHO cell clones generated by
random integration show a high variability in growth rate
and productivity [15]. The production level and the speciﬁc
protein to be expressed are also known to affect the clonal
growth rate [16]. Polyclonal clone compositions will in an
industrial setup have to go through at least 35 cell divisions
in order to include two-tiered cell banking and seed-train
expansion before reaching the ﬁnal production phase. It
was to be expected that cultivation for multiple generations
of rpAb compositions expressing different antibodies at
slightly different levels with potentially different growth
rates would lead to one or more clones taking over the
cultures and/or to clones disappearing. As we show here this
is certainly seen to some extent, but surprisingly, a few
iterations and exchange of clones with undesired charac-
teristics made it possible to establish compositions where
the rpAb composition is maintained in the ﬁnal product.
Importantly, the conceptual studies were designed to sim-
ulate a process appropriate for industrial manufacturing at
large scale. The applied process includes a two-tiered cell
banking step, which is important for a biological product for
human therapeutic use in order to secure homogenous seed
material for manufacturing throughout product lifespan.
Different alternatives could be thought of regarding
production of rpAbs. First, all antibodies in a lead com-
position could be produced, puriﬁed, and characterized
separately before being mixed in the ﬁnal drug product.
However, development costs would be high and most
likely prohibitive if more than a few clones (3–4) should be
present in the ﬁnal composition. An alternative approach
could be the use of partly separate culturing of the clones
constituting the rpAb compositions: Monoclonal Master
and Working cell banks (MCB and WCB) are prepared for
the different clones constituting the ﬁnal composition, and
each clone is thawed and cultured individually during the
whole seed-train or part of it. This would lead to a higher
degree of control over the ﬁnal composition since the
number of generations in co-culture would be lower,
Fig. 7 Comparison of the relative area of the individual anti-RSV
antibodies from two independent sets of fed batch production runs
performed with rpAb composition I. The dark bars represent the
average antibody concentration of four parallel consistency runs. The
light bars represent the average antibody concentration of the
duplicate runs initially performed with composition I (see Fig. 6a).
Samples for CIEX proﬁles were taken at day 10 (right bars) and day
12 (left bars). The standard deviation is indicated as error bars
Mol Biotechnol (2010) 45:257–266 265although care would have to be taken to avoid microbial
contamination or other manufacturing process irregularities
in multiple cell lines growing in parallel under GMP con-
ditions. Manufacturing scenarios using this approach are
described in WO 2009/129814.
We have earlier reported the use of Flp-In site-speciﬁc
integration for the generation of stable polyclonal producer
cell banks exhibiting sufﬁciently similar growth and pro-
ductivity properties to allow consistent single-batch man-
ufacturing of rpAb [13]. Sym001 (Rozrolimupab), which
comprises 25 anti-Rhesus D speciﬁc antibodies, is pro-
duced using this technology. At the time it was envisaged
that the background for this consistency was the use of site-
speciﬁc integration, which would serve to avoid genomic
position effects with respect to growth properties of the
cells, and at least to some extent result in equal expression
levels. This technology where only one copy of the anti-
body gene is stably integrated into the expressing clone
does however limit the production level of the stable pro-
ducer cell lines. This makes the Sympress
TM I technology
best suited to support niche indications. The modiﬁcations
implemented in Sympress
TM II employing random inte-
gration in an improved cell line, a much higher copy
number, use of a stringent DHFR selection system and
implementation of FACS based sorting for high producers
have led to a signiﬁcant improvement in overall produc-
tivity (approximately 10-fold) while conserving the high
batch-to-batch consistency observed with Sympress
TM I.
This makes the Sympress
TM II platform suitable for
manufacturing of drug substance for major indications.
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